C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: A post-hoc analysis from ACCENT i

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 5, 2012, Pages 568-576

  Reinisch, W ^a   Wang, Y ^b   Oddens, B J ^b   Link, R ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Medical Affairs Immunology Europe   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862777688     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04987.x     Document Type: Article

References (19)

1. Loftus EV, Sandborn WJ,. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 1-20. (Pubitemid 34733030)
2. Saro Gismera C, Lacort Fernández M, Fernandez GA, et al,. Mortality and causes of death in patients with chronic inflammatory bowel disease in Gijõn, Asturias (Spain). Rev Esp Enferm Dig 1999; 91: 199-208.
3. Card T, Hubbard R, Logan RF,. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 2003; 125: 1583-90. (Pubitemid 37500421)
4. Cottone M, Martorana G, Di Mitri R, Cammà C, Caprilli R,. Epidemiology of inflammatory bowel disease in Italy. Ital J Gastroenterol Hepatol 1999; 31: 503-7. (Pubitemid 29460326)
5. Tilg H,. Inflammatory bowel diseases: meeting of the European Crohn's Colitis Organization, 1-3 March 2007, Innsbruck, Austria. Expert Opin Ther Targets 2007; 11: 853-6. (Pubitemid 46901400)
6. Regueiro MD,. Update in medical treatment of Crohn's disease. J Clin Gastroenterol 2000; 31: 282-91.
7. Van Assche G, Vermeire S, Rutgeerts P,. Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep 2008; 10: 591-6.
8. Desai D, Faubion WA, Sandborn WJ,. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 247-55. (Pubitemid 46115394)
9. Vermeire S, Van Assche G, Rutgeerts P,. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-5. (Pubitemid 39276479)
10. Emery P, Gabay C, Kraan M, Gomez-Reino J,. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007; 27: 793-806. (Pubitemid 46906651)
11. Danese S, Fiorino G, Reinisch W,. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Therap 2011; 34: 1-10.
12. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
13. Rutgeerts P, Feagan BG, Lichtenstein GR, et al,. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
14. Colombel J-F, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
15. Schreiber S, Rutgeerts P, Fedorak RN, et al,. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18. (Pubitemid 41242673)
16. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
17. Jürgens M, Mahachie John JM, Cleynen I, et al,. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 421-7.
18. Laharie D, Mesli S, El Hajbi F, et al,. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011; 34: 462-9.
19. Kiss LS, Szamosi T, Molnar T, et al,. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011; 34: 911-22.